2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow TASK Applied Science: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
Tuberculosis, Pulmonary (2) · Tuberculosis (1)
Ethambutol (2) · Isoniazid (2) · Pyrazinamide (2) · Rifampin (2) · 2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (1) · Ethionamide (1) · Fumigant 93 (1) · GSK656 (1) · Linezolid (1) · Moxifloxacin (1) · OPC-67683 (1) · Protons (1) · bedaquiline (1) · delpazolid (1) · pretomanid (1)
South Africa (2) · Moldova (1) · Tanzania (1) · Uganda (1) · Vietnam (1)